[CH3:1][N:2]1[C:6]([CH2:7][OH:8])=[N:5][CH:4]=[N:3]1.[C:9]([C:13]1[C:14](OS(C2C=CC(C)=CC=2)(=O)=O)=[N:15][N:16]2[C:21]=1[C:20]([CH3:22])=[N:19][N:18]=[C:17]2[C:23]1[C:28]([F:29])=[CH:27][CH:26]=[C:25]([F:30])[C:24]=1[F:31])([CH3:12])([CH3:11])[CH3:10]>>[C:9]([C:13]1[C:14]([O:8][CH2:7][C:6]2[N:2]([CH3:1])[N:3]=[CH:4][N:5]=2)=[N:15][N:16]2[C:21]=1[C:20]([CH3:22])=[N:19][N:18]=[C:17]2[C:23]1[C:28]([F:29])=[CH:27][CH:26]=[C:25]([F:30])[C:24]=1[F:31])([CH3:12])([CH3:10])[CH3:11]This compound was prepared using the procedure described in Example 7, step e, using (2-methyl-2H-[1,2,4]triazol-3-yl)methanol (prepared as described in EP-A-170073) instead of (2-ethyl-2H-[1,2,4]triazol-3-yl)methanol, and using toluene-4-sulfonic acid 3-tert-butyl-4-methyl-7-(2,3,6-trifluorophenyl)pyrazolo[1,5-d][1,2,4]triazin-2-yl ester instead of toluene-4-sulfonic acid 3-tert-butyl-7-(2,5-difuorophenyl)-4-methylpyrazolo[1,5-d][1,2,4]triazin-2-yl ester. Data for the title compound: 1H NMR (400 MHz, CDCl3) δ 1.55 (9H, s), 3.07 (3H, s), 3.84 (3H, s), 5.38 (2H, s), 7.04 (1H, m), 7.41 (1H, m), 7.86 (1H, s); MS (ES+) m/e 432 [MH]+.